Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biogen scraps Alzheimer drug trials, wiping $17 billion off its market value

Biogen Inc. and partner Eisai Co. Ltd. are ending two late-stage trials for the experimental Alzheimer’s drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen’s stock, which lost more than $17 billion of the company’s value.

Read More »

A Blood Test That Can ID Alzheimer’s Risk Up To 16 Years Before Symptoms

Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.

Read More »

BioSpace Readers’ Picks: Top 10 Stories of 2018

Here is a look at BioSpace’s top 10 stories of 2018.

Read More »

Lilly partners with AC Immune for Alzheimer’s treatment

U.S. drugmaker Eli Lilly and Co. and AC Immune SA agreed to jointly develop the Swiss biotech’s potential treatment for Alzheimer’s disease.

Read More »

Lilly scraps a BACE program for Alzheimer’s

Eli Lilly scrapped a Phase II clinical trial for N3pG, a humanized IgG1 monoclonal antibody, plus BACE in the treatment of Alzheimer’s.

Read More »

Toxic “Zombie Cells” Observed in Alzheimer’s Patients

Researchers at the University of Texas Health Science Center at San Antonio found a type of cellular stress in Alzheimer’s disease for the first time that is involved in cancer and aging.

Read More »

FDA declines to approve Pain Therapeutics’ opioid drug

The U.S. FDA declined to approve Pain Therapeutics Inc.’s abuse-deterrent opioid treatment Remoxy for the fourth time.

Read More »

Investors turn wary on Biogen/Eisai Alzheimer’s drug results

Shares of Eisai Co. Ltd. plunged as much as 21 percent after the results of the company’s experimental Alzheimer’s drug being developed with partner Biogen Inc. failed to enthuse investors.

Read More »

Biogen easily tops Street estimates on Spinraza sales, raises forecast

Biogen Inc. reported far better-than-expected second-quarter 2018 profit, driven by strong demand of the company’s Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast.

Read More »

Eisai, Biogen to advance Alzheimer’s drug

Eisai Co. Ltd. and Biogen Inc. will move forward with late-stage clinical trials of their Alzheimer’s disease drug BAN2401, and the companies are working with regulators to design the next studies and gain expedited review as a breakthrough therapy.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom